Eyal Dor
Overview
Explore the profile of Eyal Dor including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
92
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Toister E, Cherry L, Lupu E, Monash A, Dor E, Levin L, et al.
Vaccines (Basel)
. 2024 Apr;
12(4).
PMID: 38675756
The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in more than seven million deaths worldwide. To reduce viral spread, the Israel Institute for Biological...
2.
Cohen N, Simon I, Hazan O, Tal A, Tzadok H, Levin L, et al.
Front Bioeng Biotechnol
. 2024 Mar;
12:1333548.
PMID: 38449674
The COVID-19 pandemic has led to high global demand for vaccines to safeguard public health. To that end, our institute has developed a recombinant viral vector vaccine utilizing a modified...
3.
Nechooshtan R, Ehrlich S, Vitikainen M, Makovitzki A, Dor E, Marcus H, et al.
Vaccines (Basel)
. 2022 Dec;
10(12).
PMID: 36560529
SARS-CoV-2 is evolving with increased transmission, host range, pathogenicity, and virulence. The original and mutant viruses escape host innate (Interferon) immunity and adaptive (Antibody) immunity, emphasizing unmet needs for high-yield,...
4.
Ben David A, Barnea A, Torgeman A, Diamant E, Dor E, Schwartz A, et al.
Vaccines (Basel)
. 2022 Sep;
10(9).
PMID: 36146601
Botulism is a paralytic disease caused by botulinum neurotoxins (BoNTs). Equine antitoxin is currently the standard therapy for botulism in human. The preparation of equine antitoxin relies on the immunization...
5.
Rosenfeld R, Alcalay R, Zvi A, Ben-David A, Noy-Porat T, Chitlaru T, et al.
Front Immunol
. 2022 Sep;
13:942317.
PMID: 36059507
Hyper-immune antisera from large mammals, in particular horses, are routinely used for life-saving anti-intoxication intervention. While highly efficient, the use of these immunotherapeutics is complicated by possible recipient reactogenicity and...
6.
Makovitzki A, Jayson A, Oren Z, Lerer E, Kafri Y, Dor E, et al.
BioTech (Basel)
. 2022 Jul;
10(4).
PMID: 35822799
The COVID-19 pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) increases the need for a rapid development of efficient vaccines. Among other vaccines in clinical trials, a recombinant...
7.
Lerer E, Oren Z, Kafri Y, Adar Y, Toister E, Cherry L, et al.
BioTech (Basel)
. 2022 Jul;
10(4).
PMID: 35822796
This study reports a highly efficient, rapid one-step purification process for the production of the recombinant vesicular stomatitis virus-based vaccine, rVSV-∆G-spike (rVSV-S), recently developed by the Israel Institute for Biological...
8.
Jayson A, Goldvaser M, Dor E, Monash A, Levin L, Cherry L, et al.
Biotechnol Prog
. 2022 May;
38(5):e3277.
PMID: 35633106
The Ambr15 system is an automated, high-throughput bioreactor platform which comprises 24 individually controlled, single-use stirred-tank reactors. This system plays a critical role in process development by reducing reagent requirements...
9.
Mechaly A, Diamant E, Alcalay R, Ben David A, Dor E, Torgeman A, et al.
Antibodies (Basel)
. 2022 Mar;
11(1).
PMID: 35323195
Botulinum neurotoxin type E (BoNT/E), the fastest acting toxin of all BoNTs, cleaves the 25 kDa synaptosomal-associated protein (SNAP-25) in motor neurons, leading to flaccid paralysis. The specific detection and...
10.
Rosen O, Jayson A, Goldvaser M, Dor E, Monash A, Levin L, et al.
Biotechnol Bioeng
. 2022 Mar;
119(7):1839-1848.
PMID: 35319097
To face the coronavirus disease 2019 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, our institute has developed the rVSV-ΔG-spike vaccine, in which the glycoprotein of...